Compounds > pirfenidone
Page last updated: 2024-08-23

pirfenidone and Endotoxin Shock

pirfenidone has been researched along with Endotoxin Shock in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aebischer, O; Benmachiche, M; Bonjour, T; Carrel, G; Castioni, J; Cosma-Rochat, M; Fournier, J; Gachoud, D; Gagliano, M; Giger, A; Greiser, J; Lamy, O; Méan, M; Mieville, A; Rouiller Larpin, N; Tusgul, S; Voruz, S; Wenger, N1
Cain, WC; Lefkowitz, DL; Lefkowitz, SS; Margolin, S; Starnes, JD; Stuart, RW1
Hale, ML; Krakauer, T; Margolin, SB; Roy, CJ; Stiles, BG1
Horikawa, T; Nakazato, H; Oku, H; Suzuki, R; Tsuruta, Y1
Nakazato, H; Oku, H; Suzuki, R; Tsuruta, Y; Yamane, S1

Other Studies

5 other study(ies) available for pirfenidone and Endotoxin Shock

ArticleYear
[What is new in 2014 for the specialist in hospital internal medicine? The point of view of university hospital chief residents].
    Revue medicale suisse, 2015, Jan-21, Volume: 11, Issue:458

    Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arterial Pressure; Catheterization, Central Venous; Diverticulitis; Emergency Service, Hospital; Hospitals, University; Humans; Hypertension; Idiopathic Pulmonary Fibrosis; Internal Medicine; Kidney; Medical Staff, Hospital; Pneumonia; Pulmonary Embolism; Pyridones; Shock, Septic; Sympathectomy; Tumor Necrosis Factor-alpha; Ultrasonography; Venous Thromboembolism; Vitamin B 12 Deficiency; Vitamin E

2015
Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone.
    International journal of immunopharmacology, 1998, Volume: 20, Issue:12

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Immunologic; Galactosamine; Injections, Intraperitoneal; Interleukin-6; Lipopolysaccharides; Macrophages, Peritoneal; Male; Mice; Mice, Inbred C57BL; Pyridones; Shock, Septic; Thioglycolates; Tumor Necrosis Factor-alpha

1998
Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B.
    Infection and immunity, 2002, Volume: 70, Issue:6

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Division; Cells, Cultured; Disease Models, Animal; Enterotoxins; Humans; Interferon-gamma; Interleukin-1; Interleukin-6; Leukocytes, Mononuclear; Male; Mice; Mice, Inbred BALB C; Pyridones; Shock, Septic; Staphylococcal Infections; Staphylococcus aureus; Superantigens; T-Lymphocytes; Tumor Necrosis Factor-alpha

2002
Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock.
    European journal of pharmacology, 2002, Jun-20, Volume: 446, Issue:1-3

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Galactosamine; Interferon-gamma; Interleukin-10; Interleukin-12; Lipopolysaccharides; Liver; Liver Failure; Mice; Mice, Inbred C57BL; Necrosis; Pyridones; Shock, Septic; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha

2002
A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level.
    European journal of pharmacology, 2002, Jun-20, Volume: 446, Issue:1-3

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Northern; Cell Line; Female; Interferon-gamma; Interleukin-10; Interleukin-6; JNK Mitogen-Activated Protein Kinases; Lipopolysaccharides; MAP Kinase Kinase 2; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Protein Biosynthesis; Protein-Tyrosine Kinases; Pyridones; Reverse Transcriptase Polymerase Chain Reaction; Shock, Septic; Tumor Necrosis Factor-alpha

2002